B. Cannella et al., Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination, AM J PATH, 157(3), 2000, pp. 933-943
Citations number
26
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Previous studies have shown that insulin-like grow-th factor-1 (IGF-1) has
beneficial effects, both clinically and histopathologically, on experimenta
l autoimmune encephalomyelitis (EAE), although results vary depending on sp
ecies and treatment regimen. The present study investigated whether IGF-1,
delivered at different time points during the acute and chronic phases of a
doptively transferred EAE in SJL mice, had the ability to affect or enhance
myelin regeneration. Central nervous system tissue sampled at different st
ages of treatment was subjected to detailed neuropathological, immunocytoch
emical and molecular analysis. The results revealed some transient clinical
amelioration and low level remyelination after IGF-1 administration during
the acute phase of EAE, However, central nervous system tissue from acute
phase treated animals sampled at chronic time points and from animals given
IGF-1 during the chronic phase revealed no enhancing effect on remyelinati
on in comparison to vehicle-treated controls. Examination of oligodendrocyt
e progenitor populations also revealed no differences between IGF-1- and ve
hicle-treated groups. At the cytokine level, the immunomodulatory molecules
TGF-beta 2 and TGF-beta 3 displayed significant decreases that may have co
ntributed to the transient nature of the effect of IGF-1 on EAE, Together w
ith evidence from previous studies, it appears doubtful that IGF-1 is a goo
d candidate for treatment in multiple sclerosis, for which EAE serves as a
major model.